Could a lower dose of thyroid hormone be just as effective for advanced cancer?
NCT ID NCT06790589
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two strategies for using levothyroxine to suppress TSH in patients with advanced thyroid cancer that cannot be fully removed. The standard approach keeps TSH very low (below 0.1), but this can cause side effects. The trial will test if a slightly higher TSH target (0.1 to 0.5) is just as safe and effective at preventing cancer progression. About 70 adults in Alberta will participate, and the main goal is to see how many are alive without their cancer getting worse after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Levothyroxine (Synthroid) oral tablet
What this could lead to
If successful, this could show that a less strict TSH target is just as effective, reducing side effects like heart problems and bone loss for patients.
What could go wrong
This is a small, early-phase study (70 participants) that may not prove non-inferiority. The results may not apply to all thyroid cancer types or stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED DIFFERENTIATED THYROID GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••